Summary
69.10 0.56(0.82%)07/03/2024
Intra-Cellular Therapies Inc (ITCI)
Intra-Cellular Therapies Inc (ITCI)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.91 | -2.95 | 1.08 | 2.61 | -0.50 | 10.40 | 407.71 | 360.67 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 69.10 | |
| Open | 67.81 | |
| High | 69.12 | |
| Low | 67.68 | |
| Volume | 370,458 | |
| Change | 0.62 | |
| Change % | 0.91 | |
| Avg Volume (20 Days) | 1,250,613 | |
| Volume/Avg Volume (20 Days) Ratio | 0.30 | |
| 52 Week Range | 45.50 - 84.89 | |
| Price vs 52 Week High | -18.60% | |
| Price vs 52 Week Low | 51.87% | |
| Range | 1.90 | |
| Gap Up/Down | -1.56 | |
Fundamentals | ||
| Market Capitalization (Mln) | 7,236 | |
| EBIDTA | -131,415,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 91.64 | |
| Book Value | 6.1500 | |
| Earnings Per Share | -1.1600 | |
| EPS Estimate Current Quarter | -0.3200 | |
| EPS Estimate Next Quarter | -0.2000 | |
| EPS Estimate Current Year | -0.5500 | |
| EPS Estimate Next Year | 1.0600 | |
| Diluted EPS (TTM) | -1.1600 | |
| Revenues | ||
| Profit Marging | -0.2157 | |
| Operating Marging (TTM) | -0.1446 | |
| Return on asset (TTM) | -0.1123 | |
| Return on equity (TTM) | -0.1807 | |
| Revenue TTM | 513,929,984 | |
| Revenue per share TTM | 5.3360 | |
| Quarterly Revenue Growth (YOY) | 0.5200 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 95,156,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 10.7836 | |
| Revenue Enterprise Value | 12.7585 | |
| EBITDA Enterprise Value | -37.1202 | |
| Shares | ||
| Shares Outstanding | 105,575,000 | |
| Shares Float | 103,340,891 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.04 | |
| Insider (%) | 2.32 | |
| Institutions (%) | 90.50 | |
06/24 10:55 EST - zacks.com
Intra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe
Intra-Cellular (ITCI) is witnessing strong Caplyta sales, driven by an increasing prescription rate. However, the company is heavily dependent on Caplyta sales for growth, which is a concern.
Intra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe
Intra-Cellular (ITCI) is witnessing strong Caplyta sales, driven by an increasing prescription rate. However, the company is heavily dependent on Caplyta sales for growth, which is a concern.
06/19 11:30 EST - zacks.com
Intra-Cellular (ITCI) Up as Second Depression Study Meets Goals
Intra-Cellular (ITCI) gains 10% after achieving key goals in the second late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.
Intra-Cellular (ITCI) Up as Second Depression Study Meets Goals
Intra-Cellular (ITCI) gains 10% after achieving key goals in the second late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.
06/19 07:30 EST - zacks.com
Intra-Cellular (ITCI) Soars 9.6%: Is Further Upside Left in the Stock?
Intra-Cellular (ITCI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Intra-Cellular (ITCI) Soars 9.6%: Is Further Upside Left in the Stock?
Intra-Cellular (ITCI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
06/19 02:08 EST - seekingalpha.com
Intra-Cellular Brightens MDD Outlook With Caplyta Success
Caplyta (lumateperone) shows significant promise as an adjunctive treatment for Major Depressive Disorder. Caplyta's unique pharmacological profile targeting serotonin, dopamine, and glutamate pathways sets it apart in the saturated MDD market. Intra-Cellular's financial stability is supported by strong sales growth and sufficient cash reserves to sustain operations until 2027.
Intra-Cellular Brightens MDD Outlook With Caplyta Success
Caplyta (lumateperone) shows significant promise as an adjunctive treatment for Major Depressive Disorder. Caplyta's unique pharmacological profile targeting serotonin, dopamine, and glutamate pathways sets it apart in the saturated MDD market. Intra-Cellular's financial stability is supported by strong sales growth and sufficient cash reserves to sustain operations until 2027.
06/18 10:37 EST - benzinga.com
Intra-Cellular Therapies' Highlights Successful Data From Second Depression Study
Tuesday, Intra-Cellular Therapies Inc ITCI released topline results from Study 502 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD).
Intra-Cellular Therapies' Highlights Successful Data From Second Depression Study
Tuesday, Intra-Cellular Therapies Inc ITCI released topline results from Study 502 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD).
06/18 07:30 EST - globenewswire.com
Intra-Cellular Therapies Announces Positive Topline Results in Second Phase 3 Trial Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
In Study 502, lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints
Intra-Cellular Therapies Announces Positive Topline Results in Second Phase 3 Trial Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
In Study 502, lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints
06/10 08:00 EST - globenewswire.com
Intra-Cellular Therapies to Present at the 45th Annual Goldman Sachs Global Healthcare Conference
NEW YORK, June 10, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 45th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 11, 2024 at 10:00 a.m. ET in Miami, FL.
Intra-Cellular Therapies to Present at the 45th Annual Goldman Sachs Global Healthcare Conference
NEW YORK, June 10, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 45th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 11, 2024 at 10:00 a.m. ET in Miami, FL.
06/06 12:35 EST - zacks.com
Why Is Intra-Cellular (ITCI) Up 1.2% Since Last Earnings Report?
Intra-Cellular (ITCI) reported earnings 30 days ago. What's next for the stock?
Why Is Intra-Cellular (ITCI) Up 1.2% Since Last Earnings Report?
Intra-Cellular (ITCI) reported earnings 30 days ago. What's next for the stock?
05/30 06:00 EST - investorplace.com
The Secret Stock Stash: 3 Overlooked Picks That Belong in Every Portfolio
While it's always comforting to bank on ideas that the masses believe in, overlooked stocks have their charm too. By targeting enterprises that relatively few investors follow, should the stars align just right, the rewards could be enormous.
The Secret Stock Stash: 3 Overlooked Picks That Belong in Every Portfolio
While it's always comforting to bank on ideas that the masses believe in, overlooked stocks have their charm too. By targeting enterprises that relatively few investors follow, should the stars align just right, the rewards could be enormous.
05/29 08:00 EST - globenewswire.com
Intra-Cellular Therapies to Present at the Jefferies Global Healthcare Conference
NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 11:00 a.m. ET in New York, NY.
Intra-Cellular Therapies to Present at the Jefferies Global Healthcare Conference
NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 11:00 a.m. ET in New York, NY.
05/23 08:00 EST - globenewswire.com
Intra-Cellular Therapies Highlights Data Presentations at the American Society of Clinical Psychopharmacology Annual Meeting
NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today highlights data presentations at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting being held in Miami, May 28 - 31, 2024.
Intra-Cellular Therapies Highlights Data Presentations at the American Society of Clinical Psychopharmacology Annual Meeting
NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today highlights data presentations at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting being held in Miami, May 28 - 31, 2024.
05/08 12:46 EST - zacks.com
Intra-Cellular (ITCI) Q1 Earnings and Sales Beat Estimates
Intra-Cellular (ITCI) reports first-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong Caplyta sales.
Intra-Cellular (ITCI) Q1 Earnings and Sales Beat Estimates
Intra-Cellular (ITCI) reports first-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong Caplyta sales.
05/07 13:47 EST - seekingalpha.com
Intra-Cellular Therapies, Inc. (ITCI) Q1 2024 Earnings Call Transcript
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI ) Q1 2024 Earnings Conference Call May 7, 2024 8:30 AM ET Company Participants Juan Sanchez - Vice President of Corporate Communications and Investor Relations Sharon Mates - Founder, Chairman and Chief Executive Officer Mark Neumann - Executive Vice President and Chief Commercial Officer Lawrence Hineline - Senior Vice President of Finance and Chief Financial Officer Suresh Durgam - Executive Vice President and Chief Medical Officer Conference Call Participants Jessica Fye - JPMorgan Brian Abrahams - RBC Capital Markets Andrew Tsai - Jefferies Charles Duncan - Cantor Fitzgerald Marc Goodman - Leerink Partners Michael DiFiore - Evercore ISI Jason Gerberry - Bank of America Securities Sumant Kulkarni - Canaccord Genuity Michael Riad - Morgan Stanley Charles Wang - Mizuho Securities Troy Langford - TD Cowen Ashwani Verma - UBS Ami Fadia - Needham Corinne Johnson - Goldman Sachs David Amsellem - Piper Sandler Joel Beatty - Baird Operator Good morning, ladies and gentlemen, and welcome to Intra-Cellular Therapies' First Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Intra-Cellular Therapies, Inc. (ITCI) Q1 2024 Earnings Call Transcript
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI ) Q1 2024 Earnings Conference Call May 7, 2024 8:30 AM ET Company Participants Juan Sanchez - Vice President of Corporate Communications and Investor Relations Sharon Mates - Founder, Chairman and Chief Executive Officer Mark Neumann - Executive Vice President and Chief Commercial Officer Lawrence Hineline - Senior Vice President of Finance and Chief Financial Officer Suresh Durgam - Executive Vice President and Chief Medical Officer Conference Call Participants Jessica Fye - JPMorgan Brian Abrahams - RBC Capital Markets Andrew Tsai - Jefferies Charles Duncan - Cantor Fitzgerald Marc Goodman - Leerink Partners Michael DiFiore - Evercore ISI Jason Gerberry - Bank of America Securities Sumant Kulkarni - Canaccord Genuity Michael Riad - Morgan Stanley Charles Wang - Mizuho Securities Troy Langford - TD Cowen Ashwani Verma - UBS Ami Fadia - Needham Corinne Johnson - Goldman Sachs David Amsellem - Piper Sandler Joel Beatty - Baird Operator Good morning, ladies and gentlemen, and welcome to Intra-Cellular Therapies' First Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
05/07 09:41 EST - zacks.com
Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Tops Revenue Estimates
Intra-Cellular Therapies (ITCI) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.46 per share a year ago.
Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Tops Revenue Estimates
Intra-Cellular Therapies (ITCI) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.46 per share a year ago.
05/07 07:30 EST - globenewswire.com
Intra-Cellular Therapies Reports First Quarter 2024 Financial Results
CAPLYTA Q1 2024 net product sales were $144.8 million , compared to $94.7 million for the same period in 2023 , representing a 53% increase
Intra-Cellular Therapies Reports First Quarter 2024 Financial Results
CAPLYTA Q1 2024 net product sales were $144.8 million , compared to $94.7 million for the same period in 2023 , representing a 53% increase
04/30 08:00 EST - globenewswire.com
Intra-Cellular Therapies to Host First Quarter 2024 Financial Results Conference Call and Webcast
NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Tuesday, May 7, 2024, to provide a corporate update and discuss details of the Company's financial results for the quarter ended March 31, 2024.
Intra-Cellular Therapies to Host First Quarter 2024 Financial Results Conference Call and Webcast
NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Tuesday, May 7, 2024, to provide a corporate update and discuss details of the Company's financial results for the quarter ended March 31, 2024.
04/30 04:38 EST - seekingalpha.com
Intra-Cellular Therapies: Positive MDD Data And Commercial Momentum Make It A Buy
The share price reaction of Intra-Cellular Therapies was not as strong as expected after the positive phase 3 results of Caplyta in major depressive disorder. Positive MDD results represent another de-risking event for the drug and should open up another large market for Caplyta, pending positive results from the second phase 3 trial. The company's commercial momentum remains strong, with strong sequential and YoY growth in the first quarter.
Intra-Cellular Therapies: Positive MDD Data And Commercial Momentum Make It A Buy
The share price reaction of Intra-Cellular Therapies was not as strong as expected after the positive phase 3 results of Caplyta in major depressive disorder. Positive MDD results represent another de-risking event for the drug and should open up another large market for Caplyta, pending positive results from the second phase 3 trial. The company's commercial momentum remains strong, with strong sequential and YoY growth in the first quarter.
04/25 11:07 EST - zacks.com
Will Intra-Cellular Therapies (ITCI) Report Negative Q1 Earnings? What You Should Know
Intra-Cellular (ITCI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Intra-Cellular Therapies (ITCI) Report Negative Q1 Earnings? What You Should Know
Intra-Cellular (ITCI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
04/24 16:01 EST - globenewswire.com
Intra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) (“Intra-Cellular Therapies”), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it has completed the sale of an additional 1,027,397 shares of its common stock at a public offering price of $73.00 per share on April 24, 2024, pursuant to the full exercise of the option granted by Intra-Cellular Therapies to the underwriters in connection with its previously announced public offering of 6,849,316 shares of common stock, which closed on April 22, 2024.
Intra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) (“Intra-Cellular Therapies”), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it has completed the sale of an additional 1,027,397 shares of its common stock at a public offering price of $73.00 per share on April 24, 2024, pursuant to the full exercise of the option granted by Intra-Cellular Therapies to the underwriters in connection with its previously announced public offering of 6,849,316 shares of common stock, which closed on April 22, 2024.
04/24 11:36 EST - investorplace.com
3 Biotech Stocks With Skyrocketing Potential: April 2024
Investing in biotech stocks is not for the faint of heart. The sector is prone to wild swings in stock prices, offering a distinctive blend of high risk and high reward.
3 Biotech Stocks With Skyrocketing Potential: April 2024
Investing in biotech stocks is not for the faint of heart. The sector is prone to wild swings in stock prices, offering a distinctive blend of high risk and high reward.